QuickView for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=D831C094D33AE78EB1FA54E89E87BB6C;jsessionid=7CD31CD252F50BD35638215522ED219F;jsessionid=6C3916FE7C5793834AD25E98FED2CE82;jsessionid=E540FEE3FA6B99D4F29F171EC3214241;jsessionid=6D2D8FE2460EA59182B992DBCDE8DAC3;jsessionid=5CA0D7CB5171B049EF0D77380876A935 (gene)

1. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
2. Clinical Evaluation of Cystic Renal Masses With Bosniak Classification by Contrast-Enhanced Ultrasou…
3. Feasibility of Surveillance for Mucinous Cystic Neoplasm of the Pancreas: A Multi-Institutional Retr…
4. Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lun…
5. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal mas…

There were no clinical trials for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=D831C094D33AE78EB1FA54E89E87BB6C;jsessionid=7CD31CD252F50BD35638215522ED219F;jsessionid=6C3916FE7C5793834AD25E98FED2CE82;jsessionid=E540FEE3FA6B99D4F29F171EC3214241;jsessionid=6D2D8FE2460EA59182B992DBCDE8DAC3;jsessionid=5CA0D7CB5171B049EF0D77380876A935